Document Detail


Angiotensin-converting enzyme inhibitors in heart failure: a role after myocardial infarction.
MedLine Citation:
PMID:  1725054     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The prognosis for clinical congestive heart failure remains poor even with modern treatment as severe ventricular dysfunction is often present at the time of clinical presentation. A substantial improvement in prognosis might be achieved through earlier intervention and a preventive approach to treatment following myocardial infarction to delay progressive ventricular dilation and the occurrence of clinical heart failure. The rationale for treatment of left ventricular dysfunction following myocardial infarction is further supported by the prognostic importance of ventricular dilation and by experimental animal studies that demonstrate that converting enzyme inhibition can improve ventricular function and survival following myocardial infarction. Similarly, clinical studies have demonstrated that converting enzyme inhibition can improve ventricular function during the year following transmural myocardial infarction. Possible mechanisms of action that require further understanding include ventricular afterload reduction and direct coronary and tissue effects of angiotensin II blockade. The further benefit to be obtained from very early intervention following myocardial infarction is currently being addressed in several studies. Large-scale studies also in progress should determine the mortality benefit of such treatment. Further questions that remain include the optimal timing of intervention, comparison with other treatments such as nitrates and beta-blockade, and also the use of appropriate combination treatments.
Authors:
N Sharpe
Related Documents :
11999634 - Recent advances in the treatment of heart failure.
3291594 - Vasodilator therapy in chronic congestive heart failure.
25276304 - Calcific left atrium: a rare consequence of endocarditis.
18163014 - Aminothiol redox alterations in patients with chronic heart failure of ischaemic or non...
6736444 - Prognostic value of q waves, r/s ratio, loss of r wave voltage, st-t segment abnormalit...
20486954 - Takotsubo cardiomyopathy induced by dobutamine infusion: a new phenomenon or an old dis...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  18 Suppl 2     ISSN:  0160-2446     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  1991  
Date Detail:
Created Date:  1992-04-28     Completed Date:  1992-04-28     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  S99-104     Citation Subset:  IM    
Affiliation:
Department of Medicine, University of Auckland School of Medicine, New Zealand.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Heart Failure / drug therapy*,  physiopathology
Humans
Myocardial Infarction / drug therapy*,  physiopathology
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Antiarrhythmic therapy and survival following myocardial infarction.
Next Document:  Prevention of chemotherapy-induced leukemia and of leukemia relapses.